CRISPR Medicine News and Chinese Society of Gene & Cell Therapy Form Media Partnership to Bridge Global Gene-Editing Research
核心洞察
CRISPR Medicine News (搜索) and the Chinese Society of Gene & Cell Therapy (搜索) announced a media partnership on August 3, 2026, to strengthen international scientific communication in gene and cell therapy.
The collaboration will produce joint content, expert interviews, trial reports and roundtables, with CMN expanding coverage of scientific and clinical developments emerging from China.
A virtual roundtable in early September 2026 will launch the partnership, followed by a CRISPR (搜索) medicine session at the CSGCT annual meeting on September 19-20, 2026, in Beijing.
CRISPR Medicine News (搜索) (CMN) and the Chinese Society of Gene & Cell Therapy (搜索) (CSGCT) announced on August 3, 2026, a media partnership aimed at strengthening international scientific communication and fostering greater collaboration across the global CRISPR (搜索), gene and cell therapy community. The agreement pairs an independent global media platform dedicated to CRISPR and genomic medicines with China's professional society for gene and cell therapy.
Under the collaboration, the two organizations will promote scientific exchange through joint content initiatives, expert interviews, trial reports, international roundtable discussions and coverage of major scientific meetings. CMN will expand its coverage of scientific and clinical developments emerging from China, while CSGCT will facilitate greater visibility of CMN's independently produced content within its professional community. Both organizations will jointly promote their flagship annual events and develop educational activities intended to strengthen dialogue between researchers, clinicians, innovators and industry across continents.
Launch Activities and Annual Meeting Session
CMN and CSGCT will co-host a virtual roundtable in early September 2026 to kick off the partnership. Jens-Ole Bock, Founder of CMN, will also chair a session on CRISPR (搜索) medicine at CSGCT's annual meeting, taking place September 19-20, 2026, in Beijing, China.
At that meeting, Bock will moderate a panel discussion in Session 4 on September 20 addressing what it takes to bring in vivo CRISPR (搜索) medicines to patients at scale, against the backdrop of the first in vivo CRISPR therapy under FDA priority review and a growing pipeline of in vivo editing programs moving through the clinic. The panel is structured around what CMN describes as the combined delivery, safety, intellectual property and translation challenges of scaling in vivo CRISPR therapies. Panelists include Yongzhong Wang of AccurEdit Therapeutics (搜索), presenting the first systemic LNP-CRISPR data from Chinese patients; Xiaoyu Liang of Edibeck Therapeutics (搜索), offering the perspective of a company building next-generation in vivo editors; Rui Tian of GeneRulor (搜索), addressing the off-target and safety assessments regulators expect in a filing; Ulrich Storz of Michalski Hütterman & Partner, on a decade of mapping CRISPR ownership and licensing requirements for launch; and José-Carlos Segovia of CIEMAT (搜索), on European experience taking gene therapies for Fanconi anaemia (搜索) and pyruvate kinase deficiency (搜索) from bench to clinic.
Independence and Safety Scrutiny
Both organizations framed the partnership as a commitment to responsible innovation. "Innovation in gene and cell therapy is increasingly global. Important scientific advances are taking place across many regions of the world, and meaningful progress depends on better communication between them," Bock said. "Through our partnership with CSGCT, we hope to encourage greater international dialogue, share developments from China with a wider audience, and support the exchange of knowledge needed to advance new therapies towards safe and accessible clinical application. At the same time, we remain committed to independent, rigorous reporting on safety and regulatory questions as this field matures - that scrutiny is essential to earning and maintaining public trust."
Zhenhua Wu, PhD, President of CSGCT, said the society "is pleased to establish this media partnership with CRISPR Medicine News (搜索). We look forward to expanding international scientific communication and supporting greater exchange between researchers and clinicians working to advance gene and cell therapies worldwide."
CMN stated that the partnership does not extend to editorial content and that it retains full independence in its reporting, including ongoing coverage of clinical trial safety and regulatory oversight in the field. The organization noted that as the field navigates recent questions around trial safety and transparency, international collaboration on shared standards becomes even more important.
Organizational Profiles
CMN describes itself as the world's leading platform for CRISPR (搜索) and genomic medicine, with a monthly readership of 35,000 across 170 countries. Since 2018, it has tracked CRISPR's journey from research tool to clinical reality, delivering weekly news, expert interviews, webinars and trial updates. CMN also convenes the field through CRISPRMED, an annual conference launched in 2024. In 2026, CMN expanded its offering with CMN Intelligence, an open-access database combined with quarterly reports tracking the global landscape of gene-editing trials. The platform states its core commitment is speeding up the clinical translation of safe gene-editing therapies for patients facing rare diseases and complex cancers.
CSGCT is a non-profit professional organization dedicated to advancing innovation and collaboration in the gene and cell therapy field. It connects scientists, clinicians, regulators, industry leaders and investors to accelerate translation of research into therapies, and promotes global integration and expanded access to innovative treatments with the goal of improving patient outcomes.